Skip to main content

Table 3 Results for the cost effectiveness analysis (Monte Carlo micro-simulation 50,000 times)

From: Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification

Population Interval QALY Incremental QALY Cost ($) Incremental cost ($) ICER ($/QALY)
Age BMI group
30–44 Underweight Annual 30.12 2467.16 Dominated
3-year 30.16 0.01 963.10 557.19 93,898.79 (vs 10-year)
10-year 30.16 405.92
Normal Annual 30.13 2489.28 Dominated
3-year 30.15 0.01 1112.80 385.93 63,295.18 (vs 6-year)
6-year 30.14 726.86
Overweight Annual 29.86 2894.63 Dominated
3-year 29.97 2678.14 Dominated
4-year 29.97 2477.31 Dominant
Obese Annual 28.88 4313.80
2-year 29.18 8965.05 Dominated
3-year 29.19 0.31 8948.87 4635.07 15,034.02 (vs Annual)
45–59 Underweight Annual 23.54 1949.99 Dominated
3-year 23.55 879.01 Dominated
10-year 23.55 408.86 Dominant
Normal Annual 23.45 2081.91 Dominated
3-year 23.48 1445.89 Dominated
6-year 23.49 1107.16 Dominant
Overweight Annual 23.17 2763.11 Dominated
3-year 23.20 2753.06 Dominated
4-year 23.26 2908.66
Obese Annual 22.27 3024.01
3-year 22.66 0.4 7647.58 4623.57 11,849.71 (vs Annual)
4-year 22.63 7348.82 Dominated
60–74 Underweight Annual 15.74 1325.15 Dominated
3-year 15.77 0.02 651.84 198.73 11,377.06 (vs 6-year)
6-year 15.75 453.10
Normal Annual 15.69 1379.50 Dominated
3-year 15.72 0.02 1039.23 319.93 18,123.44 (vs 7-year)
7-year 15.70 719.29
Overweight Annual 15.47 1481.22
3-year 15.56 0.02 1829.22 275.64 12,537.81 (vs 5-year)
5-year 15.54 0.07 1553.58 72.36 1006.48 (vs Annual)
Obese Annual 15.01 1617.53
3-year 15.23 0.22 3552.88 1935.34 8685.76 (vs Annual)
4-year 15.21 3363.21 Dominated
  1. Underlined intervals are found to be the most cost-effective strategies with willingness-to-pay threshold of $50,000. Units of costs, incremental costs and ICER is in USD$